Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Fungal Endocarditis Market

ID: MRFR/LS/17824-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Fungal Endocarditis Market Research Report By Type (Candida species, Aspergillus species, Histoplasma capsulatum), By Diagnosis (physical examination, blood test, X-ray, echocardiography, electrocardiogram), By Treatment (antifungal medication, surgery, combined treatment, voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, others) and By End User (hospital, clinics, diagnostic centers, others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Fungal Endocarditis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  49.     4.1.1 Candida species
  50.     4.1.2 Aspergillus species
  51.     4.1.3 Histoplasma capsulatum
  52.   4.2 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
  53.     4.2.1 Physical examination
  54.     4.2.2 Blood test
  55.     4.2.3 X-ray
  56.     4.2.4 Echocardiography
  57.     4.2.5 Electrocardiogram
  58.   4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
  59.     4.3.1 Antifungal medication
  60.     4.3.2 Surgery
  61.     4.3.3 Combined treatment
  62.   4.4 Food, Beverages & Nutrition, BY End-User (USD Million)
  63.     4.4.1 Hospital
  64.     4.4.2 Clinics
  65.     4.4.3 Diagnostic centers
  66.     4.4.4 Others
  67. 5 SECTION V: COMPETITIVE ANALYSIS
  68.   5.1 Competitive Landscape
  69.     5.1.1 Overview
  70.     5.1.2 Competitive Analysis
  71.     5.1.3 Market share Analysis
  72.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  73.     5.1.5 Competitive Benchmarking
  74.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  75.     5.1.7 Key developments and growth strategies
  76.       5.1.7.1 New Product Launch/Service Deployment
  77.       5.1.7.2 Merger & Acquisitions
  78.       5.1.7.3 Joint Ventures
  79.     5.1.8 Major Players Financial Matrix
  80.       5.1.8.1 Sales and Operating Income
  81.       5.1.8.2 Major Players R&D Expenditure. 2023
  82.   5.2 Company Profiles
  83.     5.2.1 Pfizer Inc (US)
  84.       5.2.1.1 Financial Overview
  85.       5.2.1.2 Products Offered
  86.       5.2.1.3 Key Developments
  87.       5.2.1.4 SWOT Analysis
  88.       5.2.1.5 Key Strategies
  89.     5.2.2 Merck & Co Inc (US)
  90.       5.2.2.1 Financial Overview
  91.       5.2.2.2 Products Offered
  92.       5.2.2.3 Key Developments
  93.       5.2.2.4 SWOT Analysis
  94.       5.2.2.5 Key Strategies
  95.     5.2.3 Astellas Pharma Inc (JP)
  96.       5.2.3.1 Financial Overview
  97.       5.2.3.2 Products Offered
  98.       5.2.3.3 Key Developments
  99.       5.2.3.4 SWOT Analysis
  100.       5.2.3.5 Key Strategies
  101.     5.2.4 Gilead Sciences Inc (US)
  102.       5.2.4.1 Financial Overview
  103.       5.2.4.2 Products Offered
  104.       5.2.4.3 Key Developments
  105.       5.2.4.4 SWOT Analysis
  106.       5.2.4.5 Key Strategies
  107.     5.2.5 Bristol-Myers Squibb Company (US)
  108.       5.2.5.1 Financial Overview
  109.       5.2.5.2 Products Offered
  110.       5.2.5.3 Key Developments
  111.       5.2.5.4 SWOT Analysis
  112.       5.2.5.5 Key Strategies
  113.     5.2.6 Novartis AG (CH)
  114.       5.2.6.1 Financial Overview
  115.       5.2.6.2 Products Offered
  116.       5.2.6.3 Key Developments
  117.       5.2.6.4 SWOT Analysis
  118.       5.2.6.5 Key Strategies
  119.     5.2.7 Roche Holding AG (CH)
  120.       5.2.7.1 Financial Overview
  121.       5.2.7.2 Products Offered
  122.       5.2.7.3 Key Developments
  123.       5.2.7.4 SWOT Analysis
  124.       5.2.7.5 Key Strategies
  125.     5.2.8 AbbVie Inc (US)
  126.       5.2.8.1 Financial Overview
  127.       5.2.8.2 Products Offered
  128.       5.2.8.3 Key Developments
  129.       5.2.8.4 SWOT Analysis
  130.       5.2.8.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 US MARKET ANALYSIS BY TYPE
  137.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  138.   6.4 US MARKET ANALYSIS BY TREATMENT
  139.   6.5 US MARKET ANALYSIS BY END-USER
  140.   6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  141.   6.7 RESEARCH PROCESS OF MRFR
  142.   6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  143.   6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  144.   6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  145.   6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  146.   6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
  147.   6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
  148.   6.14 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
  149.   6.15 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  150.   6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
  151.   6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
  152.   6.18 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
  153.   6.19 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
  154.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  155. 7 LIST OF TABLES
  156.   7.1 LIST OF ASSUMPTIONS
  157.     7.1.1
  158.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  159.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  160.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  161.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  162.     7.2.4 BY END-USER, 2025-2035 (USD Million)
  163.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  164.     7.3.1
  165.   7.4 ACQUISITION/PARTNERSHIP
  166.     7.4.1

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

  • Candida species
  • Aspergillus species
  • Histoplasma capsulatum

Food, Beverages & Nutrition By Diagnosis (USD Million, 2025-2035)

  • Physical examination
  • Blood test
  • X-ray
  • Echocardiography
  • Electrocardiogram

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

  • Antifungal medication
  • Surgery
  • Combined treatment

Food, Beverages & Nutrition By End-User (USD Million, 2025-2035)

  • Hospital
  • Clinics
  • Diagnostic centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓